https://mindmedicinelaw.com/briefing/federal-report-urges-states-to-prepare-for-psychedelics-20260826-35909The Psychedelic Journalen2026-08-26T22:03:52.741674+00:00Federal Report Urges States to Prepare for Psychedelicspsychedelic approval, FDA, state regulation, mental health, therapeutic use, policy framework, public health, psilocybin, MDMA, federal reporthttps://mindmedicinelaw.com/briefing/epa-s-new-snurs-under-tsca-implications-for-psychedelics-20260826-35636The Psychedelic Journalen2026-08-26T15:05:04.611710+00:00EPA's New SNURs Under TSCA: Implications for PsychedelicsEPA SNURs, TSCA regulations, psychedelic research, chemical substances, regulatory compliance, environmental policy, manufacture notification, chemical evaluation, industry impact, new use ruleshttps://mindmedicinelaw.com/briefing/new-ketamine-clinic-opens-in-kitsap-implications-and-outlook-20260826-35759The Psychedelic Journalen2026-08-26T15:04:50.648803+00:00New Ketamine Clinic Opens in Kitsap: Implications and Outlookketamine therapy, Kitsap Washington, psychedelic-assisted therapy, treatment-resistant depression, mental health treatment, ketamine clinic, psychedelic research, controlled substances, clinical trials, mental health policyhttps://mindmedicinelaw.com/briefing/comment-period-extended-for-7-oh-schedule-i-proposal-20260826-35624The Psychedelic Journalen2026-08-26T15:04:34.221048+00:00Comment Period Extended for 7-OH Schedule I Proposal7-hydroxymitragynine, Schedule I proposal, comment period extension, Controlled Substances Act, kratom regulation, psychoactive compounds, public health policy, research barriers, substance scheduling, stakeholder engagementhttps://mindmedicinelaw.com/briefing/fda-seeks-input-on-international-drug-scheduling-changes-20260826-35631The Psychedelic Journalen2026-08-26T15:04:21.158819+00:00FDA Seeks Input on International Drug Scheduling ChangesFDA, drug scheduling, ECDD, international drug control, public comments, psychotropic substances, narcotic drugs, abuse potential, medical use, drug policyhttps://mindmedicinelaw.com/briefing/dea-temporarily-schedules-mitragynine-derivatives-as-schedule-i-20260826-35621The Psychedelic Journalen2026-08-26T15:04:06.426615+00:00DEA Temporarily Schedules Mitragynine Derivatives as Schedule IDEA, mitragynine pseudoindoxyl, Schedule I, controlled substances, psychedelic research, public safety, regulatory controls, MGM-15, MGM-16https://mindmedicinelaw.com/briefing/psychedelic-doi-alters-mice-olfactory-behavior-implications-20260825-35829The Psychedelic Journalen2026-08-26T22:04:18.516880+00:00Psychedelic DOI Alters Mice Olfactory Behavior: Implicationspsychedelic research, DOI, olfactory behavior, mice study, neuroscience, sensory effects, clinical trials, serotonergic psychedelics, sensory processing, therapeutic applicationshttps://mindmedicinelaw.com/briefing/multi-omics-integration-in-mdd-toward-precision-psychiatry-20260825-35843The Psychedelic Journalen2026-08-26T22:04:08.024876+00:00Multi-Omics Integration in MDD: Toward Precision Psychiatrymulti-omics integration, major depressive disorder, precision psychiatry, biomarker-based diagnostics, personalized treatment, clinical trials, neuroimaging, genomics, mental health policy, psychiatric researchhttps://mindmedicinelaw.com/briefing/filament-health-s-psilocybin-supply-deal-implications-for-research-and-market-20260825-35608The Psychedelic Journalen2026-08-25T22:05:12.472559+00:00Filament Health's Psilocybin Supply Deal: Implications for Research and Marketfilament health, psilocybin supply, PEX01, psychedelic research, clinical trials, market access, therapeutic use, regulatory implications, mental health treatment, psychedelic compoundshttps://mindmedicinelaw.com/briefing/uw-s-psilocybin-retreats-for-cancer-clinical-trial-insights-20260825-35607The Psychedelic Journalen2026-08-25T22:04:45.678542+00:00UW's Psilocybin Retreats for Cancer: Clinical Trial Insightspsilocybin retreats, advanced cancer, palliative care, psychedelic therapies, clinical trial, University of Washington, mental health benefits, FDA regulations, group therapy, serotonin receptorshttps://mindmedicinelaw.com/briefing/rhelion-life-sciences-psilocybin-supply-deal-with-uw-20260825-35453The Psychedelic Journalen2026-08-25T15:05:43.217830+00:00Rhelion Life Sciences' Psilocybin Supply Deal with UWpsilocybin research, Rhelion Life Sciences, University of Washington, clinical trials, psychedelic therapies, mental health treatment, regulatory implications, biotech partnershipshttps://mindmedicinelaw.com/briefing/oregon-s-psychedelic-dataset-outpaces-historical-trials-20260825-35452The Psychedelic Journalen2026-08-25T15:04:44.499541+00:00Oregon's Psychedelic Dataset Outpaces Historical TrialsOregon psychedelic dataset, state-level data, federal regulators, psilocybin therapy, clinical trials, policy implications, data integration, psychedelic research, public health, therapeutic applicationshttps://mindmedicinelaw.com/briefing/gut-brain-axis-therapies-for-depression-in-crohn-s-disease-20260824-35799The Psychedelic Journalen2026-08-26T22:05:41.972138+00:00Gut-Brain Axis Therapies for Depression in Crohn's Diseasegut-brain axis, Crohn's disease, depression, ketamine enantiomers, microbiota-targeting compounds, vagus nerve stimulation, inflammatory bowel disease, immune activation, neuroimmune signaling, integrative treatment strategieshttps://mindmedicinelaw.com/briefing/feasibility-of-star-textstar-for-sexual-assault-survivors-20260824-35817The Psychedelic Journalen2026-08-26T22:05:27.800216+00:00Feasibility of STAR & TextSTAR for Sexual Assault Survivorssexual assault survivors, trauma recovery, STAR program, TextSTAR program, posttraumatic stress, substance misuse, psychoeducation, early intervention, mental health, opioid misusehttps://mindmedicinelaw.com/briefing/arrestins-in-gpcr-signaling-implications-for-drug-design-20260824-35830The Psychedelic Journalen2026-08-26T22:05:14.084492+00:00Arrestins in GPCR Signaling: Implications for Drug Designarrestins, GPCR signaling, drug design, neurological disorders, therapeutic strategies, biased signaling, allosteric modulators, molecular glues, cryo-electron microscopy, receptor-targeted therapieshttps://mindmedicinelaw.com/briefing/ayahuasca-s-potential-in-neuropsychiatric-drug-discovery-20260824-35831The Psychedelic Journalen2026-08-26T22:05:03.081219+00:00Ayahuasca's Potential in Neuropsychiatric Drug Discoveryayahuasca, neuropsychiatric disorders, multitarget therapeutic, drug discovery, bioactive compounds, network pharmacologyhttps://mindmedicinelaw.com/briefing/gabapentin-s-neurodegeneration-risks-emerging-insights-20260824-35844The Psychedelic Journalen2026-08-26T22:04:53.884421+00:00Gabapentin's Neurodegeneration Risks: Emerging Insightsgabapentin, neurodegeneration, neurodegenerative disorders, antiepileptic drugs, oxidative stress, excitotoxicity, SIRT1, CaMKII, cognitive decline, clinical researchhttps://mindmedicinelaw.com/briefing/proteomic-profiling-in-treatment-resistant-depression-20260824-35846The Psychedelic Journalen2026-08-26T22:04:41.470905+00:00Proteomic Profiling in Treatment-Resistant Depressiontreatment-resistant depression, extracellular vesicles, proteomic profiling, biological pathways, molecular stratification, depression research, clinical trials, neuroscience, antidepressant resistance, precision medicinehttps://mindmedicinelaw.com/briefing/fda-accelerates-psychedelic-approvals-urges-washington-action-20260824-35606The Psychedelic Journalen2026-08-25T22:04:59.816412+00:00FDA Accelerates Psychedelic Approvals, Urges Washington ActionFDA, psychedelic therapies, drug approval, clinical trials, mental health, legislative action, policy changes, market dynamics, research funding, Controlled Substances Acthttps://mindmedicinelaw.com/briefing/bmi-s-influence-on-depression-treatment-outcomes-20260824-35383The Psychedelic Journalen2026-08-25T15:05:58.306201+00:00BMI's Influence on Depression Treatment OutcomesBMI, treatment-resistant depression, systematic review, personalized medicine, pharmacotherapy, ketamine, transcranial magnetic stimulationhttps://mindmedicinelaw.com/briefing/cmps-stock-surge-implications-for-fda-psychedelic-review-20260824-35451The Psychedelic Journalen2026-08-25T15:05:25.320258+00:00CMPS Stock Surge: Implications for FDA Psychedelic ReviewCMPS stock, FDA hearing, psychedelic therapies, regulatory pathways, market dynamics, drug approval process, psilocybin research, investor confidence, mental health treatment, clinical trialshttps://mindmedicinelaw.com/briefing/ketamine-s-opioid-nature-implications-for-regulation-and-therapy-20260824-35444The Psychedelic Journalen2026-08-25T15:04:58.010610+00:00Ketamine's Opioid Nature: Implications for Regulation and Therapyketamine, opioid receptors, pharmacodynamics, mental health treatment, regulatory classification, clinical guidelineshttps://mindmedicinelaw.com/briefing/trait-responsiveness-and-placebo-effects-in-psychedelic-trials-20260823-35370The Psychedelic Journalen2026-08-25T15:06:09.365278+00:00Trait Responsiveness and Placebo Effects in Psychedelic Trialstrait responsiveness, placebo effects, psychedelic research, clinical trials, verbal suggestions, meta-analysishttps://mindmedicinelaw.com/briefing/oregon-psilocybin-services-show-long-term-benefits-20260819-35454The Psychedelic Journalen2026-08-25T15:05:11.526441+00:00Oregon Psilocybin Services Show Long-Term Benefitspsilocybin therapy, Oregon psilocybin services, mental health treatment, psychedelic research, public health policy, clinical trials, long-term benefits, serotonin receptors, psychedelic therapy, mental health outcomes